Tag Archives: atrial fibrillation programme

XENTION LTD announced the phase 2 development of its lead atrial fibrillation programme (“AF”) is underway

Posted on 2, September 2014 by

CAMBRIDGE, UK, 2-9-2014 — /EuropaWire/ — XENTION LTD (“Xention”), the Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs developing anti-arrhythmic drugs, announced today that the phase 2 development of its lead atrial fibrillation programme (“AF”) is underway. … Read the full press release →

Posted in France, Healthcare, Pharma & Biotech, United Kingdom

Tagged , , , ,